Department of Pathology, Yanbian University College of Medicine, Yanji, China.
Pathol Int. 2012 Mar;62(3):176-81. doi: 10.1111/j.1440-1827.2011.02775.x. Epub 2012 Jan 13.
To investigate the clinicopathological significance of DEK overexpression in breast cancers, a total of 196 cases, including 20 of normal tissues, 12 of intraductal hyperplasia, 31 of ductal carcinoma in situ (DCIS) and 133 of invasive ductal carcinoma of the breast, were selected from the Department of Pathology, Yanbian Tumor Hospital for immunohistochemical staining of DEK, estrogen (ER), progesterone (PR) and Ki-67 proteins. In results, DEK protein had higher positivity in DCIS, compared with the adjacent normal breast tissues. Also, DEK protein was strongly positive in invasive ductal carcinoma of the breast on immunohistochemistry, which was significantly higher than normal breast tissues. However, only two (2/12) cases of intraductal hyperplasia of the breast showed positive staining for DEK protein. Additionally, DEK overexpression was significantly correlated with the increased proliferating index of Ki-67. For the histological grade, DEK positive rate was only 39.6% in G1 breast cancers, but significantly higher in G2 (92.3%) and G3 (97.0%) cases (P<0.05). Also, a strongly positive rate of DEK was lower in Stage-0 (21.4%) and Stage-I (40.9%) compared with Stage-IIa (87.5%), Stage-IIb (89.7%) and Stage-IIIa (92.3%) (P<0.05). And DEK protein showed higher expression level in < 3 years disease free survival breast cancers than it did in ≥ 3 years disease free survival cases (P<0.05). However, no statistically difference was found among DEK expression, lymph node metastasis, and ER and PR expressions. In conclusion, DEK overexpression appears to be associated with breast cancer progression and DEK may potentially be used as a breast cancer biomarker for the early diagnosis, prognostic evaluation and therapeutic target for breast cancer.
为了研究 DEK 过表达在乳腺癌中的临床病理意义，从延边肿瘤医院病理科选择了 196 例病例，包括 20 例正常组织、12 例导管内增生、31 例导管原位癌（DCIS）和 133 例浸润性乳腺癌，进行 DEK、雌激素（ER）、孕激素（PR）和 Ki-67 蛋白的免疫组织化学染色。结果显示，DCIS 中 DEK 蛋白阳性率较高，与相邻正常乳腺组织相比。此外，浸润性乳腺癌的免疫组织化学染色中 DEK 蛋白呈强阳性，明显高于正常乳腺组织。然而，只有 2 例（2/12）乳腺导管内增生病例显示 DEK 蛋白阳性染色。此外，DEK 过表达与 Ki-67 增殖指数的增加显著相关。在组织学分级方面，G1 乳腺癌中 DEK 阳性率仅为 39.6%，但在 G2（92.3%）和 G3（97.0%）病例中明显升高（P<0.05）。此外，在 0 期（21.4%）和 I 期（40.9%）中，DEK 强阳性率低于 IIa 期（87.5%）、IIb 期（89.7%）和 IIIa 期（92.3%）（P<0.05）。在无病生存期<3 年的乳腺癌中，DEK 蛋白表达水平高于无病生存期≥3 年的乳腺癌（P<0.05）。然而，在 DEK 表达、淋巴结转移以及 ER 和 PR 表达之间未发现统计学差异。综上所述，DEK 过表达似乎与乳腺癌的进展有关，DEK 可能有望成为乳腺癌早期诊断、预后评估和治疗靶点的生物标志物。
